

Amendments to the Claims

Please cancel claim 25, without prejudice.

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below, amended claims are notated to indicated changes made and the text of pending claims not being amended are presented clean. Amendments to the following are indicated by underlining what has been added and striking-through what has been deleted.

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): An isolated protein comprising a polypeptide that is at least 95% identical to amino acid residues 23 to 67 of SEQ ID NO:10; wherein the polypeptide has antimicrobial activity.

Claim 2 (previously presented): The isolated protein of claim 1 wherein the amino acid percent identity is determined using a FASTA program with ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default.

Claim 3 (previously presented): The isolated protein of claim 1 wherein the polypeptide comprises amino acid residues 23 to 67 of SEQ ID NO:10.

Claim 4 (previously presented): An isolated polypeptide selected from the group consisting of:

- a) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- b) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;
- c) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- d) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2;

and

- e) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10.

Claim 5 (previously presented): A pharmaceutical composition comprising a polypeptide selected from the group consisting of:

- a) a protein according to claim 1;
- b) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- c) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;
- d) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- e) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2;

and

- f) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10;
- in combination with a pharmaceutically acceptable vehicle.

Claims 6-20 (canceled)

Claim 21 (previously presented): A method of treating a microbial-related disease in a mammal comprising administering to the mammal a therapeutically effective amount of a polypeptide selected from the group consisting of:

- a) amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2;
- b) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10;
- c) amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10;
- d) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- e) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;
- f) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- g) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2;
- h) amino acid residue 20 to amino acid residue 67 of SEQ ID NO:10

and

- i) amino acid residue 22 to amino acid residue 67 of SEQ ID NO:10;
- wherein said polypeptide ameliorates said disease.

Claim 22 (previously presented): The method of claim 21 wherein said microbial-related disease is associated with the eye.

Claim 23 (previously presented): The method of claim 22 wherein said microbial-related disease is conjunctivitis.

Claim 24 (previously presented): The method of claim 21 wherein said microbial-related disease is associated with the ear.

Claims 25-44 (canceled)

Claim 45 (previously presented): The isolated protein of claim 1 wherein the polypeptide comprises amino acid residues 21 to 67 of SEQ ID NO:10.

Claim 46 (previously presented): The isolated protein of claim 1 wherein the polypeptide comprises amino acid residues 1 to 67 of SEQ ID NO:10.

Claims 47-49 (canceled)

Claim 50 (previously presented): An isolated polypeptide comprising amino acid residues 23 to 67 of SEQ ID NO:10.